96 Tests PN: B216498
Components:
45x Ab-conjugated beads (S5P10 - mouse TPO ab-bead). PN: B216498A. One vial containing 100 µL of anti-mouse TPO conjugated to AimPlex Bead S5P10.
25x Biotin-detection Ab (Mouse TPO Biotin-dAb). PN: B216498B. One vial containing 100 µL of biotinylated anti-mouse TPO.
Lyophilized Standard - Mouse TPO. PN: MTPOAG. One vial containing lyophilized recombinant mouse TPO.
Application: Optimal antibody pair and antigen standard for assaying mouse TPO. To be used in conjunction with the AimPlex Mouse/Rat Basic Kit (PN: P200201) and a diluent kit. Refer to the AimPlex Multiplex Immunoassay User Manual and kit inserts for the assay procedure.
Storage: 2-8 C in the dark.
Important: Sodium azide forms explosive compounds with heavy metals. These products contain <0.05% (w/w) azide which with repeated contact with lead and copper commonly found in plumbing drains may result in the buildup of shock sensitive compounds. Dispose in accordance with regulations from your institute.
For Research Use Only. Not for use in diagnostic procedures.
Assay Specifications:
Sample types: Cell culture supernatant, platelet-poor plasma, bodily fluid and tissue/cell lysate
Sensitivity (LOD): < 30 pg/mL
Quantitation range:
LLOQ: < 100 pg/mL
ULOQ: > 20,000 pg/mL
Standard dose recovery: 70-130%
Intra-assay CV: < 10%
Inter-assay CV: < 20%
Sample volume: 15 µL/test
Description:
Thrombopoietin (THPO) (Accession P35419) also known as megakaryocyte growth and development factor (MGDF) is a glycoprotein hormone produced by the liver and kidney which regulates the production of platelets. It stimulates the production and differentiation of megakaryocytes, the bone marrow cells that bud off large numbers of platelets. Megakaryocytopoiesis is the cellular development process that leads to platelet production. The protein encoded by this gene is a humoral growth factor necessary for megakaryocyte proliferation and maturation, as well as for thrombopoiesis. This protein is the ligand for MLP/C_MPL, the product of myeloproliferative leukemia virus oncogene. Diseases associated with TPO include thrombocythemia 1 and essential thrombocythemia.
References:
Kaushansky K (2006). "Lineage-specific hematopoietic growth factors". N. Engl. J. Med. 354 (19): 2034–45. doi:10.1056/NEJMra052706. PMID 16687716.
Kuter DJ, Goodnough LT, Romo J, et al. (2001). "Thrombopoietin therapy increases platelet yields in healthy platelet donors". Blood 98 (5): 1339–45. doi:10.1182/blood.V98.5.1339. PMID 11520780.
Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ (December 2001). "Thrombocytopenia caused by the development of antibodies to thrombopoietin". Blood 98 (12): 3241–8. doi:10.1182/blood.V98.12.3241. PMID 11719360.
Imbach P, Crowther M (August 2011). "Thrombopoietin-receptor agonists for primary immune thrombocytopenia". N. Engl. J. Med. 365 (8): 734–41. doi:10.1056/NEJMct1014202. PMID 21864167.